Prevention of herpes simplex virus eye disease: A cost-effectiveness analysis

Archives of Ophthalmology

Volumn 121, Issue 1, 2003, Pages 108-112

  Lairson, David R ^a,c   Begley, Charles E ^a   Reynolds, Thomas F ^a   Wilhelmus, Kirk R ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b CULLEN EYE INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; EYE DISEASE; HEALTH SURVEY; HERPES SIMPLEX VIRUS; HUMAN; KERATITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICARE; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; UNITED STATES;

EID: 0037253254     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.1.108     Document Type: Article

References (27)

1. Liesegang TJ, Melton LJ III, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex: incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107:1155-1159.
2. Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med. 1998;339:300-306.
3. Drummond M, Backhouse M. Assessing the economic benefits of antiherpes therapy. J Med Virol. 1993;suppl 1:51-57.
4. Engel JP. Long-term suppression of genital herpes. JAMA. 1998;280:928-929.
5. Handsfield HH, Stone KM, Wasserheit JN. Prevention agenda for genital herpes. Sex Transm Dis. 1999;26:228-231.
6. Randolph AG, Hartshorn RM, Washington AE. Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Obstet Gynecol. 1996;88:603-610.
7. Scott LL, Alexander J. Cost-effectiveness of acyclovir suppression to prevent recurrent genital herpes in term pregnancy. Am J Perinatol. 1998;15:57-62.
8. Herpetic Eye Disease Study Group. Predictors of recurrent herpes simplex virus keratitis. Cornea. 2001;20:123-128.
9. Herpetic Eye Disease Study Group. Manual of Operations. Springfield, Va: National Technical Information Service; 1994. Accession No. PB97-112999.
10. Gold MR. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
11. Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex virus eye disease. Arch Ophthalmol. 2000;118:1030-1036.
12. Medical Economics Co. Red Book. Montvale, NJ: Medical Economics Co; 2001.
13. McDonnell P. Empirical or culture-guided therapy for microbial keratitis? A plea for data. Arch Ophthalmol. 1996;114:84-87.
14. Centers for Medicare & Medicaid Services. National Physician Fee Schedule [database online]. Available at: http://cms.hhs.gov/physicians/pfs/. Accessed September 4, 2001.
15. MapQuest.com, Inc, and Navigation Technologies. MapQuest Web site. Available at: http://www.mapquest.com. Accessed September 2001 to December 2001.
16. Bureau of Labor Statistics, US Department of Labor. Current Population Survey. Available at: http://www.bls.census.gov/cps/cpsmain.htm. Accessed September 17-20, 2001.
17. Medical Expenditure Panel Survey [database on CD-ROM]. Rockville, Md: US Dept of Health and Human Services, Agency for Healthcare Research and Quality; 1997.
18. Wilhelmus KR, Coster DJ, Donovan HC, Falcon MG, Jones BR. Prognostic indicators of herpetic keratitis: analysis of a 5-year observation period after corneal ulceration. Arch Ophthalmol. 1981;99:1578-1582.
19. US Census Bureau. US POPClock projection. Available at: http:// www.census.gov. Accessed January 2002.
20. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol. 2000;118:47-51.
21. Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings SR. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA. 1999;282:2156-2163.
22. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-481.
23. Barron BA, Gee L, Hauck WW, et al. Herpetic Eye Disease Study: a controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1871-1882.
24. Wilhelmus KR, Gee L, Hauck WW, et al. Herpetic Eye Disease Study: a controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1883-1896.
25. Norn MS. Dendritic (herpetic) keratitis, I: incidence-seasonal variationrecurrence rate-visual impairment-therapy. Acta Ophthalmol (Copenh). 1970;48:91-107.
26. Claoue C, De Cock R. The spectrum of herpes simplex virus disease of the anterior segment in the 1990s. Acta Ophthalmol Scand. 1996;74:407-410.
27. Phillips CV. The economics of "more research is needed." Int J Epidemiol. 2001;30:771-776.